Progesterone antagonists and progesterone receptor modulators

Bibliography

• PHILIBERT D, DERAEDT R, TEUTSCH G: RU 38486: a potent antiglucocorticoid M vivo. VII International Congress of Pharmacology Tokyo, Japan (1981).
   Google Scholar
• SPITZ IM, CROXATTO HB, ROBBINS A: Antiprogestins: mechanism of action and contraceptive potential. Ann. Rev Pharmacol Toxicol (1996) 36:47–81.
   PubMed Web of Science ®Google Scholar
• LEONHARDT SA, EDWARDS DP: Mechanism of action of progesterone antagonists. Exp. Biol. Med. (Maywood) (2002) 227:969–980.
   PubMed Web of Science ®Google Scholar
• GIANGRANDE PH, MCDONNELL DP: The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Frog. Horn. Res. (1999) 54:291-313; discussion 313–314.
   Google Scholar
• KASTNER P, KRUST A, TURCOTTE B et al.: Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. (1990) 9:1603–1614.
   PubMed Web of Science ®Google Scholar
• WAGNER BL, NORRIS JD, KNOTTS TA, WEIGEL NL, MCDONNELL DP: The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Ma Cell. Biol. (1998) 18:1369–1378.
   Web of Science ®Google Scholar
• LIU Z, AUBOEUF D, WONG J et al: Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc. Natl. Acad. Sci. USA (2002) 99:7940–7944.
   PubMed Web of Science ®Google Scholar
• SPITZ IM, CHWALISZ K: Progesterone receptor modulators and progesterone antagonists in women's health. Steroids (2000) 65:807–815.
   PubMed Web of Science ®Google Scholar
• SPITZ IM: Preface. Steroids (2000) 65:543–544.
   Web of Science ®Google Scholar
• ELGER W, BARTLEY J, SCHNEIDER B,KAUFMANN G, SCHUBERT G, CHWALISZ K: Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids (2000) 65:713–723.
   PubMed Web of Science ®Google Scholar
• KLEIN HITPASS L, CATO AC, HENDERSON D, RYFFEL GU: Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res. (1991) 19:1227–1234.
   PubMed Web of Science ®Google Scholar
• GASS EK, LEONHARDT SA, NORDEEN SK, EDWARDS DP: The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid M vitro and in vivo, but have distinct effects on receptor conformation. Endocrinology (1998) 139: 1905-1919.
   Google Scholar
• ONATE SA, TSAI SY, TSAI MJ, O'MALLEY BW: Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science (1995) 270:1354–1357.
   PubMed Web of Science ®Google Scholar
• VEGETO E, ALLAN GE SCHRADER WT, TSAI MJ, MCDONNELL DP, O'MALLEY BW: The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell (1992) 69:703–713.
   PubMed Web of Science ®Google Scholar
• ••Important paper showing the relevance ofthe terminal 42 amino acids in the C-terminal tail of the PR in determining the biological response.
   Google Scholar
• BENHAMOU B, GARCIA T, LEROUGE T et al.: A single amino acid that determines the sensitivity of progesterone receptors to RU486. Science (1992) 255:206–209.
   PubMed Web of Science ®Google Scholar
• TUNG L, MOHAMED MK, HOEFFLER JP, TAKIMOTO GS, HORWITZ KB: Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mel Endocrine]. (1993) 7:1256–1265.
   PubMed Web of Science ®Google Scholar
• VEGETO E, SHAHBAZ MM, WEN DX, GOLDMAN ME, O'MALLEY BW, MCDONNELL DP: Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. MM. Endocrine]. (1993) 7:1244–1255.
   PubMed Web of Science ®Google Scholar
• MCDONNELL DP, SHAHBAZ MM, VEGETO E, GOLDMAN ME: The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity. J. Steroid Biochem. Ma Biol. (1994) 48:425–432.
   PubMed Web of Science ®Google Scholar
• MCDONNELL DP, GOLDMAN ME: RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. 1 Biol. Chem. (1994) 269:11945–11949.
   PubMed Web of Science ®Google Scholar
• ••Important paper demonstrating thetransdominant repressor effect of the PR-A isoform.
   Google Scholar
• MCPHAIL MK. J. Physiol (1934) 83:145–156.
   Google Scholar
• PHILIBERT D: RU38486: An original multifaceted antihormone in vivo. In: Adrenal Steroid Antagonism. M Agarwal (Ed.), Walter de Gruyter and Co., Berlin (1984):77–101.
   Google Scholar
• FUHRMANN U, HESS STUMPP H, CLEVE A et al.: Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. Med. Chem. (2000) 43:5010–5016.
   Web of Science ®Google Scholar
• SARTORIUS CA, TUNG L, TAKIMOTO GS, HORWITZ KB: Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. I Biol. Chem. (1993) 268:9262–9266.
   Web of Science ®Google Scholar
• BECK CA, WEIGEL NL, MOYER ML, NORDEEN SK, EDWARDS DP: The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc. Nati Acad. Sd. USA (1993) 90:4441–4445.
   PubMed Web of Science ®Google Scholar
• WAGNER BL, POLLIO G, LEONHARDT S et al: 16 alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. Proc. Natl. Acad. Sci. USA (1996) 93:8739–8744.
   PubMed Web of Science ®Google Scholar
• GLASIER A, THONG KJ, DEWAR M, MACKIE M, BAIRD DT: Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl. I Med. (1992) 327:1041–1044.
   PubMed Web of Science ®Google Scholar
• WEBB AM, RUSSELL J, ELSTEIN M: Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. Br. Med. J. (1992) 305:927–931.
   PubMed Web of Science ®Google Scholar
• ASHOK PW, STALDER C, WAGAARACHCHI PT, FLETT GM, MELVIN L, TEMPLETON A: A randomised study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. Br. J. Obstet. Cynaecol. (2002) 109:553–560.
   Google Scholar
• VON HERTZEN H, PIAGGIO G, DING J et al.: Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet (2002) 360:1803–1810.
   PubMed Web of Science ®Google Scholar
• ASHOK PW, WAGAARACHCHI PT, FLETT GM, TEMPLETON A: Mifepristone as a late post-coital contraceptive. Hum. Reprod. (2001) 16:72–75.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION TASK FORCE ON POSTOVULATORY METHODS OF FERTILITY REGULATION: Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet (1999) 353:697–702.
   PubMed Web of Science ®Google Scholar
• ••Important paper demonstrating the efficacy of 10 mg mifepristone as an effective agent in emergency contraception
   Google Scholar
• XIAO BL, VON HERTZEN H, ZHAO H, PIAGGIO G: A randomized double-blind comparison of two single doses of mifepristone for emergency contraception. Hum. Reprod. (2002) 17:3084–3089.
   PubMed Web of Science ®Google Scholar
• TRUSSELL J, RODRIGUEZ G, ELLERTSON C: New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception (1998) 57:363–369.
   PubMed Web of Science ®Google Scholar
• WILCOX AJ, WEINBERG CR, BAIRD DD: Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl. J Med. (1995) 333:1517–1521.
   Google Scholar
• GRAVANIS A, SCHAISON G, GEORGE M et al.: Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. I Clin. Endocrinol. Metab. (1985) 60:156–163.
   PubMed Web of Science ®Google Scholar
• •Paper demonstrating the agonist effect of mifepristone in women.
   Google Scholar
• HOD GEN GD, VAN UEM JF, CHILLIK CF et al.: Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hum. Reprod. (1994) 9\(Suppl. 1):77–81.
   Google Scholar
• ••Important paper that was the first studydemonstrating the antiproliferative effect of mifepristone.
   Google Scholar
• SLAYDEN OD, ZELINSKI-WOOTEN MB, CHWALISZ K, STOUFFER RL, BRENNER RM: Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. Hum. Reprod. (1998) 13:269–277.
   PubMed Web of Science ®Google Scholar
• SLAYDEN OD, BRENNER RM: RU 486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (Macaca mulatta) .1 Clin. Endocrinol. Metab. (1994) 78:440–448.
   PubMed Web of Science ®Google Scholar
• BAIRD DT, BROWN A, CRITCHLEY HO, WILLIAMS AR, LIN S, CHENG L: Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum. Reprod. (2003) 18:61–68.
   PubMed Web of Science ®Google Scholar
• GROW DR, WILLIAMS RF, HSIU JG, HODGEN GD: Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. Gin. Endocrinol. Metab. (1996) 81:1933–1939.
   PubMed Web of Science ®Google Scholar
• ZELINSKI-WOOTEN MB, SLAYDEN OD, CHWALISZ K, HESS DL, BRENNER RM, STOUFFER RL: Chronic treatment of female rhesus monkeys with low doses of the antiprogestin ZK 137 316: establishment of a regimen that permits normal menstrual cyclicity. Hum. Reprod. (1998) 13:259–267.
   PubMed Web of Science ®Google Scholar
• CHWALISZ K, BRENNER RM, FUHRMANN UU, HESS STUMPP H, ELGER W: Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids (2000) 65:741–751.
   PubMed Web of Science ®Google Scholar
• KOJI T, CHEDID M, RUBIN JS et al: Progesterone-dependent expression of keratinocyte growth factor mRNA in stromal cells of the primate endometrium: keratinocyte growth factor as a progestomedin. Cell Biol. (1994) 125:393–401.
   PubMed Web of Science ®Google Scholar
• GROW DR, REECE MT, HSIU JG et al: Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: a 1-year primate study on contraception and amenorrhea. Feral Steil]. (1998) 69:936–943.
   PubMed Web of Science ®Google Scholar
• GREB RR, HEIKINHEIMO 0, WILLIAMS RF, HOD GEN GD, GOODMAN AL: Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo. Hum. Reprod. (1997) 12:1280–1292.
   PubMed Web of Science ®Google Scholar
• HEIKINHEIMO 0, HSIU JG, GORDON K et al.: Endometrial effects of RU486 in primates-antiproliferative action despite signs of estrogen action and increased cyclin-B expression. I Steroid Biochem. Mol. Biol. (1996) 59:179–190.
   Google Scholar
• PARTHASARATHY S, MORALES AJ, MURPHY AA: Antioxidant: a new role for RU-486 and related compounds. I Clin. Invest. (1994) 94:1990–1995.
   PubMed Web of Science ®Google Scholar
• NEULEN J, WILLIAMS RF, BRECKWOLDT M, CHWALISZ K, BAULIEU EE, HOD GEN GD: Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of post-receptor proliferative mechanisms. Hum. Reprod. (1996) 11:1533–1537.
   PubMed Web of Science ®Google Scholar
• BRENNER RM, SLAYDEN OD, CRITCHLEY HO: Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction (2002) 124:167–172.
   PubMed Web of Science ®Google Scholar
• •Paper showing the potential role of the AR in the antiproliferative effect.
   Google Scholar
• SLAYDEN OD, BRENNER RM: Flutamide counteracts the antiprofiferative effects of antiprogestins in the primate endometrium. j Clin. Endocrinol Metab. (2003) 88:946–949.
   PubMed Web of Science ®Google Scholar
• CHWALISZ K, STOCKEMANN K, FRITZEMEIER KH, FUHRMANN U: Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. Hum. Reprod. Update (1998) 4:570–583.
   PubMed Web of Science ®Google Scholar
• RUMPEL E, MICHNA H, KUHNEL W: Morphology of the rat uterus after long-term treatment with progesterone antagonists. Anat. Anz. (1993) 175:141–149.
   Google Scholar
• BIGSBY RM, YOUNG PC: Estrogenic effects of the antiprogestin onapristone (ZK98.299) in the rodent uterus. Jim. Obstet. Cynecol (1994) 171:188–194.
   PubMed Web of Science ®Google Scholar
• NEWFIELD RS, SPITZ IM, ISACSON C, NEW MI: Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin. Endocrinol (Oxf) (2001) 54:399–404.
   PubMed Web of Science ®Google Scholar
• GRUNBERG SM: Role of antiprogestational therapy for meningiomas. Hum. Reprod. (1994) 9\(Suppl. 1):202–207.
   Google Scholar
• GRUNBERG SM, RANKIN C, TOWNSEND J et al.: Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. American Society of Clinical Oncology San Francisco, CA, USA (2001) 20.
   Google Scholar
• GRUNBERG SM, WEISS MH, SPITZ IM et al.: Treatment of unresecatable meningiomas with the antiprogesterone agent mifepristone. Neurosurg. (1991) 74:861–864.
   Web of Science ®Google Scholar
• MARTINEAU PA, LEVENTAL M: Large endometrial polyp in a patient on long-term mifepristone therapy. I Ultrasound Med. (2000) 19:487–489.
   PubMed Web of Science ®Google Scholar
• FLEISCHER AC, WHEELER JE, YEH IT,KRAVITZ B, JENSEN C, MACDONALD B: Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. I Ultrasound Med. (1999) 18:503–512.
   PubMed Web of Science ®Google Scholar
• LIEDMAN R, LINDAHL B, AND OLF E, WILLEN R, INGVAR C, RANSTAM J: Disaccordance between estimation of endometrial thickness as measured by transvaginal ultrasound compared with hysteroscopy and directed biopsy in breast cancer patients treated with tamoxifen. Anticancer Res. (2000) 20:4889–4891.
   PubMed Web of Science ®Google Scholar
• MURPHY AA, CASTELLANO PZ: RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri. Carr: Opin. Obstet. Cynecol (1994) 6:269–278.
   Google Scholar
• MURPHY AA, KETTEL LM, MORALES AJ, ROBERTS V, PARMLEY T, YEN SS: Endometrial effects of long-term low-dose administration of RU486. Feral. Sterd. (1995) 63:761–766.
   PubMed Web of Science ®Google Scholar
• EISINGER SH, MELDRUM S, FISCELLA K, LE ROUX HD, GUZICK DS: Low-dose mifepristone for uterine leiomyomata. Obstet. Cynecol (2003) 101:243–250.
   Web of Science ®Google Scholar
• CROXATTO HB, KOVACS L, MASSAI R et al.: Effects of long-term low-dose mifepristone on reproductive function in women. Hum. Reprod. (1998) 13:793–798.
   PubMed Web of Science ®Google Scholar
• ••Important study on the long-term effect ofmifepristone in women.
   Google Scholar
• LAMBERTS SW, KOPER JW, DE JONG FH: The endocrine effects of long-term treatment with mifepristone (RU 486). I Clin. Endocrinol. Metab. (1991) 73:187–191.
   PubMed Web of Science ®Google Scholar
• HEIKINHEIMO 0, RANTA S, GRUNBERG S, LAHTEENMAKI P, SPITZ IM: Alterations in the pituitary-thyroid and pituitary-adrenal axes-consequences of long-term mifepristone treatment. Metabolism (1997) 46:292–296.
   PubMed Web of Science ®Google Scholar
• HEIKINHEIMO 0, RANTA S, GRUNBERG S, SPITZ IM: Alterations in sex steroids and gonadotropins in post-menopausal women subsequent to long-term mifepristone administration. Steroids (2000) 65:831–836.
   PubMed Web of Science ®Google Scholar
• SCHMIDT M, LOFFLER G: RU486 is a potent inhibitor of aromatase induction in human breast adipose tissue stromal cells. Steroid Biochem. Ma Biol. (1997) 60:197–204.
   PubMed Web of Science ®Google Scholar
• TSENG L, MAZELLA J, SUN B: Modulation of aromatase activity in human endometrial stromal cells by steroids, tamoxifen and RU 486. Endocrinology (1986) 118:1312–1318.
   PubMed Web of Science ®Google Scholar
• CROXATTO HB, SALVATIERRA AM, CROXATTO HD, FUENTEALBA B: Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum. Reprod. (1993) 8:201–207.
   PubMed Web of Science ®Google Scholar
• VVEIHUA Z, SAJI S, MAKINEN S et al.: Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc. Nati Acad. Sci USA (2000) 97:5936–5941.
   PubMed Web of Science ®Google Scholar
• HALL JM, MCDONNELL DP: The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology (1999) 140:5566–5578.
   PubMed Web of Science ®Google Scholar
• ZOU A, MARSCHKE KB, ARNOLD KE et al.: Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. MM. Endocrinol (1999) 13:418–430.
   PubMed Web of Science ®Google Scholar
• MULAC JERICEVIC B, MULLINAX RA, DEMAYO FJ, LYDON JP, CONNEELY OM: Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science (2000) 289:1751–1754.
   PubMed Web of Science ®Google Scholar
• ••Important study showing the proliferativeeffect on the PR-B isoform.
   Google Scholar
• ENGLUND K, BLANCK A, GUSTAVSSON I et al.: Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. I. Clin. Endocrinol Metab. (1998) 83:4092–4096.
   PubMed Web of Science ®Google Scholar
• BRANDON DD, BETHEA CL, STRAWN EY et al.: Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am. I Obstet. Cynecol (1993) 169:78–85.
   PubMed Web of Science ®Google Scholar
• YEN SSC: Use of antiprogestins in the management of endometriosis and leiomyoma. MS Donaldson, L Dorflinger, SS Brown, LZ Benet (Eds). In: Clinical Applications of Mifepristone (RU496) and other Antiprogestins. National Academy Press, Washington DC (1993):189–209.
   Google Scholar
• YANG Y, ZHENG S, LI K: Treatment of Uterine Leimyoma by two different doses of mifepristone. Chin. I Obstet. Cynecol (1996) 31:624–626.
   Google Scholar
• ZENG C, GU M, HUANG H: [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone]. Zhonghua Fu Chan Ke Za Zhi (1998) 33:490–492.
   PubMedGoogle Scholar
• CHWALISZ K, PARKER L, WILLIAMSON S: Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM). J. Soc. Cynecol Investig. (2003) 10:301A.
   Google Scholar
• KETTEL LM, MURPHY AA, MORALES AJ, RIVIER J, VALE W, YEN SS: Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Feral. Stern. (1993) 60:642–646.
   PubMed Web of Science ®Google Scholar
• KETTEL LM, MURPHY AA, MORALES AJ, ULMANN A, BAULIEU EE, YEN SS: Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil. Stern. (1996) 65:23–28.
   PubMed Web of Science ®Google Scholar
• KETTEL LM, MURPHY AA, MORALES AJ, YEN SS: Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am. Obstet. Cynecol (1998) 178:1151–1156.
   PubMed Web of Science ®Google Scholar
• HAN S, SIDELL N: RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway. I Clin. Endocrinol Metab. (2003) 88:713–719.
   PubMed Web of Science ®Google Scholar
• BYGDEMAN M, DANIELSSON KG, MARIONS L, SWAHN ML: Contraceptive use of antiprogestin. Ear. J. Contracept. Reprod. Health Care (1999) 4:103–107.
   PubMedGoogle Scholar
• SPITZ IM, VAN LOOK PF, COELINGH BENNINK HJ: The use of progesterone antagonists and progesterone receptor modulators in contraception. Steroids (2000) 65:817–823.
   PubMed Web of Science ®Google Scholar
• CAMERON ST, CRITCHLEY HO, THONG KJ, BUCKLEY CH, WILLIAMS AR, BAIRD DT: Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum. Reprod. (1996) 11:2518–2526.
   PubMed Web of Science ®Google Scholar
• BROWN A, CHENG L, LIN S, BAIRD DT: Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J. Clin. Endocrinol Metab. (2002) 87:63–70.
   PubMed Web of Science ®Google Scholar
• SARKAR NN: The potential of mifepristone (RU486) as a female contraceptive drug. Lit. I Clin. Pract. (2002) 56:140–144.
   PubMed Web of Science ®Google Scholar
• BORMAN SM, SCHWINOF KM, NIEMEYER C, CHWALISZ K, STOUFFER RL, ZELINSKI WOOTEN MB: Low-dose antiprogestin treatment prevents pregnancy in rhesus monkeys and is reversible after 1 year of treatment. Hum. Reprod. (2003) 18:69–76.
   PubMed Web of Science ®Google Scholar
• MARIONS L, DANIELSSON KG, SWAHN ML, BYGDEMAN M: Contraceptive efficacy of low doses of mifepristone. Feral. Stern. (1998) 70:813–816.
   PubMed Web of Science ®Google Scholar
• MARIONS L, VISKI S, GEMZELL-DANIELSSON K et al.: Contraceptive efficacy of daily administration of 0.5 mg mifepristone. Hum. Reprod. (1999) 14:2788–2790.
   Google Scholar
• GEMZELL DANIELSSON K, SWAHN ML, SVALANDER P, BYGDEMAN M: Early luteal phase treatment with mifepristone (RU 486) for fertility regulation. Hum. Reprod. (1993) 8:870–873.
   PubMed Web of Science ®Google Scholar
• HAPANGAMA DK, BROWN A, GLASIER AF, BAIRD DT: Feasibility of administering mifepristone as a once a month contraceptive pill. Hum. Reprod. (2001) 16:1145–1150.
   PubMed Web of Science ®Google Scholar
• WORLD HEALTH ORGANIZATION TASK FORCE ON POST-OVULATORY METHODS OF FERTILITY REGULATION: Menstrual regulation by mifepristone plus prostaglandin: results from a multicentre trial. Hum. Reprod. (1995) 10:308–314.
   PubMed Web of Science ®Google Scholar
• SWAHN ML, BYGDEMAN M, CHEN JK et al.: Once-a-month treatment with a combination of mifepristone and the prostaglandin analogue misoprostol. Hum. Reprod. (1999) 14:485–488.
   PubMed Web of Science ®Google Scholar
• GEMZELL DANIELSSON K, VAN HEUSDEN AM, KILLICK SR et al: Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum. Reprod. (2002) 17:2588–2593.
   PubMed Web of Science ®Google Scholar
• WANG Y, O'MALLEY BW Jr, TSAI SY,O'MALLEY BW: A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. USA (1994) 91:8180-8184. Important paper demonstrating GeneSwitch.
   Google Scholar
• BURCIN MM, SCHIEDNER G, KOCHANEK S, TSAI SY, O'MALLEY BW: Adenovirus-mediated regulable target gene expression in vivo. Proc. Natl. Acad. Sci. USA (1999) 96:355–360.
   PubMed Web of Science ®Google Scholar
• SMITH LC, NORDSTROM JL: Advances in plasmid gene delivery and expression in skeletal muscle. Can: Opin. MM. The]: (2000) 2:150–154.
   PubMed Web of Science ®Google Scholar
• ABRUZZESE RV, GODIN D, MEHTA V et al.: Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system. MM. The]: (2000) 2:276–287.
   PubMed Web of Science ®Google Scholar
• NORDSTROM JL: The antiprogestin-dependent GeneSwitch® system for regulated gene therapy. Steroids (In press).
   Google Scholar
• MANGAL RK, WIEHLE RD, POINDEXTER AN 3rd, WEIGEL NL: Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. J. Steroid Biochem. Biol. (1997) 63:195–202.
   PubMed Web of Science ®Google Scholar
• ARNETT MANSFIELD RL, DEFAZIO A, WAIN GV et al.: Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res. (2001) 61:4576–4582.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN AJ, BARBIERI RL, DOUBILET PM, FINE C, SCHIFF I: A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri. Feral. Steril. (1988) 49:404–409.
   PubMed Web of Science ®Google Scholar
• SPITZ IM: Progesterone antagonists and progesterone receptor modulators: an overview. Steroids (2003) (In press).
   Google Scholar